50 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs http://www.zacks.com/stock/news/740314/roche-rhhby-2019-sales-solid-on-robust-show-by-new-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-740314 Jan 30, 2020 - Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Amgen Inc (AMGN) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/01/31/amgen-inc-amgn-q4-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Jan 31, 2020 - AMGN earnings call for the period ending December 31, 2019.
Q4 GDP 2.1%, In-Line with Q3; Plus Q4 Earnings from VZ, KO & More http://www.zacks.com/stock/news/740766/q4-gdp-21-in-line-with-q3-plus-q4-earnings-from-vz-ko-more?cid=CS-ZC-FT-ahead_of_wall_street-740766 Jan 30, 2020 - Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.
Economic Data Deluge http://www.zacks.com/stock/news/740776/economic-data-deluge?cid=CS-ZC--economic_highlights-740776 Jan 30, 2020 - Economic Data Deluge
Amazon Beats Big on Q4 Bottom Line; Plus V, AMGN http://www.zacks.com/stock/news/741455/amazon-beats-big-on-q4-bottom-line-plus-v-amgn?cid=CS-ZC-FT-analyst_blog|earnings_article-741455 Jan 30, 2020 - Expectations for Q4 earnings were on the low side, both at Zacks and on the street, so take this giant bottom-line beat with a grain of salt.
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat http://www.zacks.com/stock/news/742396/amgen-amgn-stock-down-despite-q4-earnings-revenue-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-742396 Jan 31, 2020 - Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748888 Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod http://www.zacks.com/stock/news/750705/biotech-stock-roundup-earnings-updates-from-vrtx-amgn-gild-aimt-gains-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-750705 Feb 05, 2020 - Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results? http://www.zacks.com/stock/news/760880/can-biotech-etfs-gain-on-mixed-q4-earnings-results?cid=CS-ZC-FT-etf_news_and_commentary-760880 Feb 11, 2020 - Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
J&J Files Application for Darzalex Label Expansion With FDA http://www.zacks.com/stock/news/760090/jj-files-application-for-darzalex-label-expansion-with-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-760090 Feb 11, 2020 - J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.

Pages: 12345

<<<Page 5